Genotyping

Every one of the 500,000 UK Biobank participants will have their DNA scanned on a new type of genotyping chip that captures both common and rare genetic variants in a single test. This matters because existing genome-wide studies typically miss rare variants that may have outsized effects on disease risk. The new chips combine three layers of information: a whole-genome scan for common variants, a targeted look at structural changes such as deletions and duplications, and a deep read of exome regions where protein-altering mutations occur. By applying these chips to the entire UK Biobank cohort, researchers can infer haplotype phase—the pattern of which variants sit together on the same chromosome—more accurately than in standard studies, using methods that exploit shared ancestry within populations. If this succeeds, the resulting dataset will become a permanent resource for connecting genetic variation to health outcomes. Researchers worldwide will be able to impute rare variants from reference panels such as 1000Genomes and UK10K, turning the Biobank into a scaffold for discovering disease mechanisms that common-variant scans alone cannot reach. The work is primarily a fundamental science infrastructure project—it builds the foundation for future discoveries rather than delivering a specific application today.